Pyxis Oncology, INC

Pyxis Oncology announced a $50 million private placement financing to advance its lead drug candidate, MICVO, through key clinical milestones.

Pyxis Oncology, Inc. announced the results of its Annual Meeting of Stockholders held on June 15, 2026, including the election of directors and ratification of its independent auditor.

Pyxis Oncology announced its first quarter 2026 financial results, highlighting progress in its micvotabart pelidotin (MICVO) clinical development program and providing an updated cash runway into Q4 2026.

Pyxis Oncology amends prior 8-K to detail CEO Lara Sullivan's separation agreement, including continued salary, health benefits, and accelerated equity vesting.

Pyxis Oncology announced full year 2025 financial results and positive clinical updates for its lead cancer therapeutic, MICVO, in head and neck cancer.

Pyxis Oncology announces the departure of CEO Dr. Lara Sullivan and the appointment of current director Tom Civik as Interim CEO to ensure strategic continuity.

Pyxis Oncology filed its Q1 2026 Form 10-Q, detailing a net loss of $23.3 million and highlighting progress in its MICVO clinical development programs.

Pyxis Oncology reported increased net losses and a going concern warning, while advancing its lead oncology candidate, micvotabart pelidotin, with positive preliminary HNSCC clinical data and Fast Track Designation.

Pyxis Oncology reported increased losses in Q2 2025 but highlighted positive clinical data and Fast Track designation for its lead oncology candidate, micvotabart pelidotin.

Pyxis Oncology's Q1 2025 results show a net loss of $21.2 million, with strategic focus shifting towards advancing micvotabart pelidotin, particularly in R/M HNSCC.

Pyxis Oncology reports a net loss of $41.8 million for the nine months ended September 30, 2024, while highlighting progress in its clinical programs for PYX-201 and PYX-106.

Pyxis Oncology reports a net loss of $20.6 million for the six months ended June 30, 2024, alongside updates on its clinical programs and financial position.

Pyxis Oncology announced positive preliminary Phase 1 data for its lead oncology candidate MICVO in HNSCC, both as monotherapy and in combination with KEYTRUDA, but reported significant losses and substantial doubt about its ability to continue as a going concern.

Pyxis Oncology focuses on advancing its lead candidate, micvotabart pelidotin, for head and neck cancer treatment following encouraging Phase 1 trial results, while reporting a net loss of $77.3 million for 2024.

Pyxis Oncology's annual 10-K filing details the company's clinical progress, financial status, and strategic direction, highlighting its focus on novel cancer therapeutics.

Jakob Dupont, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Pyxis Oncology's Principal Financial & Accounting Officer, Jitendra Wadhane, received grants of 109,461 restricted stock units and 262,635 stock options.

Pyxis Oncology's Director, John L. Flavin, was granted 45,867 stock options with an exercise price of $1.36, vesting fully on the first anniversary of the grant date.

Michael A. Metzger, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Pyxis Oncology Director Freda Lewis-Hall was granted 45,867 stock options with a $1.36 exercise price, vesting in one year.

Pyxis Oncology Director Darren S Cline acquired 45,867 stock options with an exercise price of $1.36, vesting in one year.

Pyxis Oncology, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 15, 2026, to elect directors and ratify auditor appointment.

Pyxis Oncology will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Pyxis Oncology announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections and auditor ratification.

Pyxis Oncology is asking stockholders to approve an amendment to its 2021 Equity and Incentive Plan to increase the available shares by 5,500,000 at a special meeting on October 23, 2024.

Pyxis Oncology will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Pyxis Oncology announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, to vote on director elections and the ratification of its independent accounting firm.

Pyxis Oncology, Inc.'s President, CEO, and Chief Medical Officer, Lara Sullivan, has increased her beneficial ownership to 11.21% of the company's common stock following a new stock option grant.

Several Biotechnology Value Funds and Mark N. Lampert have jointly filed a Schedule 13G, disclosing beneficial ownership of Pyxis Oncology, Inc. common stock and warrants.

GordonMD Global Investments LP and affiliated entities report beneficial ownership of 10,024,909 shares, representing 12.1% of Pyxis Oncology, Inc.'s common stock.

Laurion Capital Management LP and its co-managing members have disclosed a 7.72% beneficial ownership stake in Pyxis Oncology, Inc., totaling 4,796,479 shares of common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported a 1.3% beneficial ownership stake in Pyxis Oncology, Inc. as of September 30, 2025.

GordonMD Global Investments LP and its affiliates have reported a 6.2% beneficial ownership stake in Pyxis Oncology, Inc., totaling 3,834,740 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Pyxis Oncology, Inc. as of June 30, 2025.